Abbonarsi

Screening for Cognitive Deficits Using the Montreal Cognitive Assessment Tool in Outpatients ≥65 Years of Age With Heart Failure - 06/08/11

Doi : 10.1016/j.amjcard.2010.12.021 
Karen Harkness, RN, PhD a, Catherine Demers, MD, MSc b, , George A. Heckman, MD, MSc c, Robert S. McKelvie, MD, PhD b
a Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada 
b Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada 
c Department of Health Studies and Gerontology, University of Waterloo, Waterloo, Ontario, Canada 

Corresponding author: Tel: 905-521-2100, ext 73324; fax: 905-521-5053

Riassunto

There is strong evidence to suggest that heart failure (HF) is an independent risk factor for cognitive impairment (CI). The combination of CI and HF is associated with increased mortality, repeat hospitalization, and poor quality of life. The purpose of this pilot study was to determine the presence of CI in older patients with HF using the Montreal Cognitive Assessment (MoCA), a brief screening instrument for CI. We conducted a cross-sectional descriptive study using the MoCA in outpatients with HF who were ≥65 years of age. Forty-four patients (mean ± SD 76 ± 6.6 years of age) completed the MoCA. More than 70% of patients scored below the MoCA cutoff score of 26, suggesting the presence of CI. However, 91% of patients with New York Heart Association classes III to IV versus 52% of patients with classes I to II had a MoCA score <26 (p = 0.004). Patients with a recent hospital admission were more likely to have a MoCA score <26 versus patients without a recent hospital admission (89% vs 62%, respectively, p <0.045). Cognitive domain subscores showing significant differences (p <0.01) were short-term memory, visuospatial function, executive function, and language. In conclusion, this study sample represented a group of older patients with HF and no suspected or documented CI, but screening with the MoCA detected CI in >70% of the sample. The presence of CI was significantly more common in patients with advanced HF symptoms or a recent hospitalization. Future studies need to determine if the MoCA can identify the presence of CI that is predictive of adverse clinical outcomes in the HF population.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Dr. Harkness was a trainee in the FUTURE program of Cardiovascular Nurse Scientists and was supported by a research fellowship from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Dr. Demers was supported by a Career Scientist Award from the Ministry of Health and Long-Term Care of Ontario, Canada.


© 2011  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 107 - N° 8

P. 1203-1207 - aprile 2011 Ritorno al numero
Articolo precedente Articolo precedente
  • Population-Based Analysis of Class Effect of β Blockers in Heart Failure
  • Darius Lucian Lazarus, Cynthia Anne Jackevicius, Hassan Behlouli, Helen Johansen, Louise Pilote
| Articolo seguente Articolo seguente
  • Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure
  • Maciej Banach, Vikas Bhatia, Margaret A. Feller, Marjan Mujib, Ravi V. Desai, Mustafa I. Ahmed, Jason L. Guichard, Inmaculada Aban, Thomas E. Love, Wilbert S. Aronow, Michel White, Prakash Deedwania, Gregg Fonarow, Ali Ahmed

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.